ID

35764

Description

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics; ODM derived from: https://clinicaltrials.gov/show/NCT02197520

Lien

https://clinicaltrials.gov/show/NCT02197520

Mots-clés

Versions (1)
  1. 21/03/2019 21/03/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

21 mars 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Diabetes Mellitus, Type 2 NCT02197520

Anglais

Eligibility Diabetes Mellitus, Type 2 NCT02197520

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
stable glycated hemoglobin (hba1c) less than (<) 10.0 percent (%)
Description

Hemoglobin A1c measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0474680
stable dose of either 0.2 to 1.5 units per kilogram per day (u/kg/day) basal insulin or a total daily insulin dose l<2.0 units per kilogram (u/kg)
Description

Basal insulin Unit/kilogram/day | Insulin Daily Dose Unit/kilogram

Type de données

boolean

Alias
UMLS CUI [1,1]
C0650607
UMLS CUI [1,2]
C1532634
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C2348070
UMLS CUI [2,3]
C1300561
c-peptide <0.3 nanomole per liter (nmol/l)
Description

Insulin C-peptide measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0202100
stable body during the last 2 months
Description

Body Stable

Type de données

boolean

Alias
UMLS CUI [1,1]
C1268086
UMLS CUI [1,2]
C0205360
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
corrected qt interval (qtc) prolongation greater than (>) 500 milliseconds (ms) or have any other abnormality in the 12 lead
Description

Prolonged QTc interval | 12 lead ECG Abnormality

Type de données

boolean

Alias
UMLS CUI [1]
C1560305
UMLS CUI [2,1]
C0430456
UMLS CUI [2,2]
C1704258
abnormal blood pressure
Description

Abnormal blood pressure

Type de données

boolean

Alias
UMLS CUI [1]
C0005826
a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from type 1 diabetes mellitus (t1dm)), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
Description

Cardiovascular Diseases | Respiration Disorders | Liver diseases | Kidney Diseases | Gastrointestinal Diseases | Endocrine System Diseases | Exception Insulin-Dependent Diabetes Mellitus | Hematological Disease | Nervous system disorder | Disease Changing Drug absorption | Disease Changing Drug metabolism | Disease Changing Drug elimination | Disease Causing Investigational New Drugs At risk | Disease Interferes with Interpretation Research data

Type de données

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C0035204
UMLS CUI [3]
C0023895
UMLS CUI [4]
C0022658
UMLS CUI [5]
C0017178
UMLS CUI [6]
C0014130
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0011854
UMLS CUI [8]
C0018939
UMLS CUI [9]
C0027765
UMLS CUI [10,1]
C0012634
UMLS CUI [10,2]
C0392747
UMLS CUI [10,3]
C0678745
UMLS CUI [11,1]
C0012634
UMLS CUI [11,2]
C0392747
UMLS CUI [11,3]
C0683140
UMLS CUI [12,1]
C0012634
UMLS CUI [12,2]
C0392747
UMLS CUI [12,3]
C0683141
UMLS CUI [13,1]
C0012634
UMLS CUI [13,2]
C0678227
UMLS CUI [13,3]
C0013230
UMLS CUI [13,4]
C1444641
UMLS CUI [14,1]
C0012634
UMLS CUI [14,2]
C0521102
UMLS CUI [14,3]
C0459471
UMLS CUI [14,4]
C0681873
currently treated with oral antidiabetic drugs (oads) (excluding metformin and dipeptidyl peptidase-4 (dpp4) inhibitors), or glucagon-like peptide-1 (glp-1) agonists or intend to use over-the counter or prescription medication, herbal medications, or nutritional supplements that affect pg or insulin sensitivity, impact on hypoglycemic awareness or promote weight loss within 4 weeks prior to randomization
Description

Antidiabetics Oral | Exception Metformin | Exception DPP-4 Inhibitor | GLP-1 Receptor Agonist | Drugs, Non-Prescription | Prescription Drugs | Herbal medicine | Dietary Supplements | Pharmaceutical Preparations Affecting Plasma glucose sensitivity | Pharmaceutical Preparations Affecting Insulin sensitivity | Pharmaceutical Preparations Impact Awareness Hypoglycemia | Weight-Loss Agents

Type de données

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1527415
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0025598
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C3537225
UMLS CUI [4]
C2917359
UMLS CUI [5]
C0013231
UMLS CUI [6]
C0304227
UMLS CUI [7]
C2240391
UMLS CUI [8]
C0242295
UMLS CUI [9,1]
C0013227
UMLS CUI [9,2]
C0392760
UMLS CUI [9,3]
C0455280
UMLS CUI [9,4]
C0020517
UMLS CUI [10,1]
C0013227
UMLS CUI [10,2]
C0392760
UMLS CUI [10,3]
C0021641
UMLS CUI [10,4]
C0020517
UMLS CUI [11,1]
C0013227
UMLS CUI [11,2]
C4049986
UMLS CUI [11,3]
C0004448
UMLS CUI [11,4]
C0020615
UMLS CUI [12]
C0376606
fasting triglycerides (tgs) >400 milligrams per deciliter (mg/dl) (4.52 millimoles per liter (mmol/l))
Description

Serum fasting triglyceride measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0582824
have used systemic or inhaled corticosteroids/glucocorticoid therapy (excluding topical, intra-articular, and intraocular preparations) within 4 weeks prior to randomization
Description

CORTICOSTEROIDS FOR SYSTEMIC USE | Glucocorticoids Systemic | Adrenal Cortex Hormones by Inhalation | Glucocorticoids by Inhalation | Exception Topical agents | Exception Pharmaceutical Preparations Intraarticular | Exception Pharmaceutical Preparations Intraocular

Type de données

boolean

Alias
UMLS CUI [1]
C3653708
UMLS CUI [2,1]
C0017710
UMLS CUI [2,2]
C0205373
UMLS CUI [3,1]
C0001617
UMLS CUI [3,2]
C0205535
UMLS CUI [4,1]
C0017710
UMLS CUI [4,2]
C0205535
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C1710439
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0013227
UMLS CUI [6,3]
C1522204
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0013227
UMLS CUI [7,3]
C1522223
currently receive insulin by pump or insulin degludec
Description

Insulin Receive Pump | Insulin degludec

Type de données

boolean

Alias
UMLS CUI [1,1]
C0021641
UMLS CUI [1,2]
C1514756
UMLS CUI [1,3]
C0182537
UMLS CUI [2]
C3491971
poorly controlled diabetes or known to have poor awareness of hypoglycemia
Description

Poorly controlled diabetes mellitus | Awareness Poor Hypoglycemia

Type de données

boolean

Alias
UMLS CUI [1]
C0554876
UMLS CUI [2,1]
C0004448
UMLS CUI [2,2]
C0542537
UMLS CUI [2,3]
C0020615
history of gastroparesis or gastrointestinal malabsorption
Description

Gastroparesis | Malabsorption gastrointestinal

Type de données

boolean

Alias
UMLS CUI [1]
C0152020
UMLS CUI [2,1]
C3714745
UMLS CUI [2,2]
C0521362
require treatment with any drug other than insulin to treat diabetes
Description

Requirement Pharmacotherapy Diabetes Mellitus | Exception Insulin

Type de données

boolean

Alias
UMLS CUI [1,1]
C1514873
UMLS CUI [1,2]
C0013216
UMLS CUI [1,3]
C0011849
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0021641
previous history of proliferative retinopathy
Description

Proliferative retinopathy

Type de données

boolean

Alias
UMLS CUI [1]
C0339467
excessive consumers of xanthines
Description

Consumer Excessive Xanthines

Type de données

boolean

Alias
UMLS CUI [1,1]
C1707496
UMLS CUI [1,2]
C0442802
UMLS CUI [1,3]
C0043318
Retour au début de la page

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT02197520

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Hemoglobin A1c measurement
Item
stable glycated hemoglobin (hba1c) less than (<) 10.0 percent (%)
boolean
C0474680 (UMLS CUI [1])
Basal insulin Unit/kilogram/day | Insulin Daily Dose Unit/kilogram
Item
stable dose of either 0.2 to 1.5 units per kilogram per day (u/kg/day) basal insulin or a total daily insulin dose l<2.0 units per kilogram (u/kg)
boolean
C0650607 (UMLS CUI [1,1])
C1532634 (UMLS CUI [1,2])
C0021641 (UMLS CUI [2,1])
C2348070 (UMLS CUI [2,2])
C1300561 (UMLS CUI [2,3])
Insulin C-peptide measurement
Item
c-peptide <0.3 nanomole per liter (nmol/l)
boolean
C0202100 (UMLS CUI [1])
Body Stable
Item
stable body during the last 2 months
boolean
C1268086 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Prolonged QTc interval | 12 lead ECG Abnormality
Item
corrected qt interval (qtc) prolongation greater than (>) 500 milliseconds (ms) or have any other abnormality in the 12 lead
boolean
C1560305 (UMLS CUI [1])
C0430456 (UMLS CUI [2,1])
C1704258 (UMLS CUI [2,2])
Abnormal blood pressure
Item
abnormal blood pressure
boolean
C0005826 (UMLS CUI [1])
Cardiovascular Diseases | Respiration Disorders | Liver diseases | Kidney Diseases | Gastrointestinal Diseases | Endocrine System Diseases | Exception Insulin-Dependent Diabetes Mellitus | Hematological Disease | Nervous system disorder | Disease Changing Drug absorption | Disease Changing Drug metabolism | Disease Changing Drug elimination | Disease Causing Investigational New Drugs At risk | Disease Interferes with Interpretation Research data
Item
a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from type 1 diabetes mellitus (t1dm)), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
boolean
C0007222 (UMLS CUI [1])
C0035204 (UMLS CUI [2])
C0023895 (UMLS CUI [3])
C0022658 (UMLS CUI [4])
C0017178 (UMLS CUI [5])
C0014130 (UMLS CUI [6])
C1705847 (UMLS CUI [7,1])
C0011854 (UMLS CUI [7,2])
C0018939 (UMLS CUI [8])
C0027765 (UMLS CUI [9])
C0012634 (UMLS CUI [10,1])
C0392747 (UMLS CUI [10,2])
C0678745 (UMLS CUI [10,3])
C0012634 (UMLS CUI [11,1])
C0392747 (UMLS CUI [11,2])
C0683140 (UMLS CUI [11,3])
C0012634 (UMLS CUI [12,1])
C0392747 (UMLS CUI [12,2])
C0683141 (UMLS CUI [12,3])
C0012634 (UMLS CUI [13,1])
C0678227 (UMLS CUI [13,2])
C0013230 (UMLS CUI [13,3])
C1444641 (UMLS CUI [13,4])
C0012634 (UMLS CUI [14,1])
C0521102 (UMLS CUI [14,2])
C0459471 (UMLS CUI [14,3])
C0681873 (UMLS CUI [14,4])
Antidiabetics Oral | Exception Metformin | Exception DPP-4 Inhibitor | GLP-1 Receptor Agonist | Drugs, Non-Prescription | Prescription Drugs | Herbal medicine | Dietary Supplements | Pharmaceutical Preparations Affecting Plasma glucose sensitivity | Pharmaceutical Preparations Affecting Insulin sensitivity | Pharmaceutical Preparations Impact Awareness Hypoglycemia | Weight-Loss Agents
Item
currently treated with oral antidiabetic drugs (oads) (excluding metformin and dipeptidyl peptidase-4 (dpp4) inhibitors), or glucagon-like peptide-1 (glp-1) agonists or intend to use over-the counter or prescription medication, herbal medications, or nutritional supplements that affect pg or insulin sensitivity, impact on hypoglycemic awareness or promote weight loss within 4 weeks prior to randomization
boolean
C0935929 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C3537225 (UMLS CUI [3,2])
C2917359 (UMLS CUI [4])
C0013231 (UMLS CUI [5])
C0304227 (UMLS CUI [6])
C2240391 (UMLS CUI [7])
C0242295 (UMLS CUI [8])
C0013227 (UMLS CUI [9,1])
C0392760 (UMLS CUI [9,2])
C0455280 (UMLS CUI [9,3])
C0020517 (UMLS CUI [9,4])
C0013227 (UMLS CUI [10,1])
C0392760 (UMLS CUI [10,2])
C0021641 (UMLS CUI [10,3])
C0020517 (UMLS CUI [10,4])
C0013227 (UMLS CUI [11,1])
C4049986 (UMLS CUI [11,2])
C0004448 (UMLS CUI [11,3])
C0020615 (UMLS CUI [11,4])
C0376606 (UMLS CUI [12])
Serum fasting triglyceride measurement
Item
fasting triglycerides (tgs) >400 milligrams per deciliter (mg/dl) (4.52 millimoles per liter (mmol/l))
boolean
C0582824 (UMLS CUI [1])
CORTICOSTEROIDS FOR SYSTEMIC USE | Glucocorticoids Systemic | Adrenal Cortex Hormones by Inhalation | Glucocorticoids by Inhalation | Exception Topical agents | Exception Pharmaceutical Preparations Intraarticular | Exception Pharmaceutical Preparations Intraocular
Item
have used systemic or inhaled corticosteroids/glucocorticoid therapy (excluding topical, intra-articular, and intraocular preparations) within 4 weeks prior to randomization
boolean
C3653708 (UMLS CUI [1])
C0017710 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C0001617 (UMLS CUI [3,1])
C0205535 (UMLS CUI [3,2])
C0017710 (UMLS CUI [4,1])
C0205535 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C1710439 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0013227 (UMLS CUI [6,2])
C1522204 (UMLS CUI [6,3])
C1705847 (UMLS CUI [7,1])
C0013227 (UMLS CUI [7,2])
C1522223 (UMLS CUI [7,3])
Insulin Receive Pump | Insulin degludec
Item
currently receive insulin by pump or insulin degludec
boolean
C0021641 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C0182537 (UMLS CUI [1,3])
C3491971 (UMLS CUI [2])
Poorly controlled diabetes mellitus | Awareness Poor Hypoglycemia
Item
poorly controlled diabetes or known to have poor awareness of hypoglycemia
boolean
C0554876 (UMLS CUI [1])
C0004448 (UMLS CUI [2,1])
C0542537 (UMLS CUI [2,2])
C0020615 (UMLS CUI [2,3])
Gastroparesis | Malabsorption gastrointestinal
Item
history of gastroparesis or gastrointestinal malabsorption
boolean
C0152020 (UMLS CUI [1])
C3714745 (UMLS CUI [2,1])
C0521362 (UMLS CUI [2,2])
Requirement Pharmacotherapy Diabetes Mellitus | Exception Insulin
Item
require treatment with any drug other than insulin to treat diabetes
boolean
C1514873 (UMLS CUI [1,1])
C0013216 (UMLS CUI [1,2])
C0011849 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0021641 (UMLS CUI [2,2])
Proliferative retinopathy
Item
previous history of proliferative retinopathy
boolean
C0339467 (UMLS CUI [1])
Consumer Excessive Xanthines
Item
excessive consumers of xanthines
boolean
C1707496 (UMLS CUI [1,1])
C0442802 (UMLS CUI [1,2])
C0043318 (UMLS CUI [1,3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial